Auxilium Biotechnologies
Auxilium Biotechnologies develops 3D bioprinting technology for producing implantable medical devices, with a focus on peripheral nerve repair.
- CEO / Founder
- Jacob Koffler
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $7.19M
- Latest Round
- Unattributed - II
- Key Investors
- Sequoia, CF Ventures, Innovation Partnerships, University of California
Technology & Products
Key Products
AMP-1 bioprinting platform, bioprinting solutions and implantable medical devices for traumatic nervous system injuries.
Technological Advantage
Ability to fabricate complex biomedical structures in space, which is not possible with conventional Earth-based 3D bioprinting methods.
Differentiation
Value Proposition
Delivers precise and uniform medical implants through microgravity-based 3D bioprinting, overcoming the manufacturing limitations of Earth-based processes.
How They Differentiate
Focuses on space-based biomanufacturing to achieve microgravity-enabled structural advantages, setting it apart from traditional bioprinting companies.
Market & Competition
Target Customers
Medical institutions and patients requiring nerve repair treatments
Industry Verticals
["Biomedical","Neurological"]
Competitors
Organovo Holdings; Aspect Biosystems; Regeneron Pharmaceuticals
Growth & Milestones
Growth Metrics
Successful deployment on the ISS and development of novel medical devices
Major Milestones
["Successful launch and operation of the AMP-1 bioprinter on the ISS","Development of the Gen 1.0 NeuroSpan Bridge"]
Notable Customers
Starlab Space; clinical trial participants (multicenter study)